Phase III randomized trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage 3 and 4 nasopharyngeal cancer of the endemic variety

医学 放射治疗 化疗 鼻咽癌 内科学 阶段(地层学) 癌症 顺铂 肿瘤科 外科 胃肠病学 生物 古生物学
作者
Joseph Wee,Eng Huat Tan,Bee Choo Tai,Hee-Kit Wong,S. S. Leong,Terence Tan,Eu Tiong Chua,K. M. Lee,Edwin Yang,David Machin
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:22 (14_suppl): 5500-5500 被引量:6
标识
DOI:10.1200/jco.2004.22.90140.5500
摘要

5500 Background: Intergroup 00–99 study for Nasopharyngeal Cancer (NPC) showed a benefit of adding chemotherapy to radiotherapy (RT). This study aimed to confirm the findings of 00–99 in patients from an endemic region. Specific objectives were to compare the rates of distant metastases, disease free (DFS) and overall survival (OS). Methods: 221 patients were randomized between 9/1997 to 5/2003. 220 are included in this analysis. 109 received radiotherapy (R) alone and 111 had chemo-radiotherapy (C). Patients were all staged by CT / MR, CXR, liver and bone imaging. All had AJCC(1997) Stage 3 or 4 disease as well as WHO Type II or III histology. All patients (C & R) received 70Gy in 7 wks using standard RT portals and techniques. Those on (C) received concurrently cisplatin (25mg/m2 D1–4) on wks 1,4 and 7 of RT and adjuvant cisplatin (20mg/m2 D1–4) and 5FU (1000mg/m2 D1–4) every 4 wks (wk 11, 15, 19) for 3 cycles following completion of RT. Results: All patients were followed up for a minimum of 6 mths. 45% had Stage III and 54% Stage IV disease. 2 patients were non-compliant in the R arm. In the C arm, 40% had dose reduction / reduced cycles of chemo during the concurrent phase; 31% did not receive any adjuvant chemotherapy; and another 27% had dose reduction / reduced or delayed cycles of chemo. 6 patients had their RT dose reduced. To date, 59 patients (37 R, 22 C) have died. Cause of death was disease-related for 51 (32 R, 19 C) . Median survival time for R was 49.9 months, but this has not been reached for those on C. 2-year DFS rates were 62% for R and 76% for C. Hazard ratio (HR) was 0.67 (95% CI: 0.42 to 1.08, p = 0.10). 2-year cumulative incidence rate for distant metastasis was 28% (95% CI 18% to 37%) for R and 14% (95% CI 7% to 21%) for C. (p = 0.034). 2-year OS rates were 77% for R and 85% for C respectively. The HR estimate was 0.54 (95% CI: 0.32 to 0.89, p = 0.02). Conclusions: This trial confirms the results of Intergroup 0099 and the results are shown to be applicable to the endemic type of NPC. This study also confirms that chemotherapy improves distant control in NPC. No significant financial relationships to disclose.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zz完成签到,获得积分10
1秒前
天天快乐应助ritayanyan88采纳,获得10
1秒前
研友_8K2QJZ发布了新的文献求助10
1秒前
严俊东发布了新的文献求助10
1秒前
66完成签到,获得积分10
1秒前
李健应助典雅天玉采纳,获得10
2秒前
3秒前
felicia12138完成签到 ,获得积分10
4秒前
秋菊的显眼完成签到,获得积分10
6秒前
上官若男应助sun采纳,获得10
6秒前
AKA蜻蜓队长完成签到,获得积分10
7秒前
汉堡包应助严俊东采纳,获得10
10秒前
zdy完成签到,获得积分10
11秒前
11秒前
占问柳完成签到,获得积分10
14秒前
14秒前
LUO完成签到,获得积分10
14秒前
李健应助uniphoton采纳,获得10
15秒前
hhhhhh完成签到,获得积分10
16秒前
Akim应助nightmare采纳,获得10
18秒前
一片叶子完成签到,获得积分10
19秒前
krito完成签到,获得积分10
19秒前
xfye发布了新的文献求助20
19秒前
研友_8K2QJZ发布了新的文献求助10
21秒前
丘比特应助魔幻高烽采纳,获得10
22秒前
Damon完成签到 ,获得积分10
23秒前
星辰大海应助krito采纳,获得10
23秒前
WUHUIWEN完成签到,获得积分10
24秒前
邱邵芸完成签到 ,获得积分10
24秒前
Ihang完成签到 ,获得积分10
24秒前
HEIKU举报Kk求助涉嫌违规
25秒前
所所应助棒棒采纳,获得10
26秒前
29秒前
Shane完成签到,获得积分10
29秒前
chenlike完成签到,获得积分10
29秒前
wrr完成签到,获得积分10
32秒前
文艺大米完成签到 ,获得积分10
33秒前
香蕉觅云应助LUO采纳,获得10
34秒前
魔幻高烽发布了新的文献求助10
34秒前
现代完成签到,获得积分10
34秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137211
求助须知:如何正确求助?哪些是违规求助? 2788244
关于积分的说明 7785274
捐赠科研通 2444247
什么是DOI,文献DOI怎么找? 1299869
科研通“疑难数据库(出版商)”最低求助积分说明 625606
版权声明 601023